Physician profile
Michael Brad Eckstein
NPI 1134265614
$4,913.51
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $983 · 2021: $1,127 · 2022: $1,238 · 2023: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $413.17 | 2019-2022 | |
| Abbvie INC. | $402.31 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $387.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $377.39 | 2019-2022 | |
| Lilly USA, LLC | $329.00 | 2019-2022 | |
| Amarin Pharma, INC. | $291.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $284.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.99 | 2019-2022 | |
| Novo Nordisk INC | $239.14 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $233.86 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.40 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $181.25 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.22 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $138.39 | 2019-2022 | |
| Astellas Pharma US INC | $136.66 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $102.26 | 2022 | |
| Pfizer INC. | $87.17 | 2019-2022 | |
| Abbott Laboratories | $75.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.79 | 2020-2021 | |
| Sanofi Pasteur INC. | $56.98 | 2019-2021 | |
| Optinose US, INC. | $49.27 | 2022 | |
| Eisai INC. | $46.38 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $40.11 | 2022 | |
| Esperion Therapeutics, INC. | $37.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.39 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.53 | 2019-2022 | |
| Shire North American Group INC | $28.32 | 2019 | |
| Allergan, INC. | $27.31 | 2019 | |
| Dynavax Technologies Corporation | $26.94 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $26.00 | 2021 | |
| Dexcom, INC. | $20.43 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $16.76 | 2022 | |
| Radius Health, INC. | $16.19 | 2019 | |
| Genentech USA, INC. | $15.97 | 2021 | |
| Endo Pharmaceuticals INC. | $13.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.43 | 2021 | |
| Nabriva Therapeutics, Plc | $13.19 | 2020 | |
| Lifescan, INC. | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eckstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.